000119842 001__ 119842 000119842 005__ 20240319081011.0 000119842 0247_ $$2doi$$a10.3390/cancers14205100 000119842 0248_ $$2sideral$$a130629 000119842 037__ $$aART-2022-130629 000119842 041__ $$aeng 000119842 100__ $$aMorote, Juan 000119842 245__ $$aA clinically significant prostate cancer predictive model using digital rectal examination prostate volume category to stratify initial prostate cancer suspicion and reduce magnetic resonance imaging demand 000119842 260__ $$c2022 000119842 5060_ $$aAccess copy available to the general public$$fUnrestricted 000119842 5203_ $$aA predictive model including age, PCa family history, biopsy status (initial vs repeat), DRE (normal vs abnormal), serum prostate-specific antigen (PSA), and DRE prostate volume ca-tegory was developed to stratify initial PCa suspicion in 1486 men with PSA > 3 ng/mL and/or abnormal DRE, in whom mpMRI followed; 2- to 4-core TRUS-guided biopsies where Prostate Imaging Report and Data System (PI-RADS) > 3 lesions and/or 12-core TRUS systematic biopsies were performed in one academic institution between 1 January 2016–31 December 2019. The csPCa detection rate, defined as International Society of Uro-Pathology grade group 2 or higher, was 36.9%. An external validation of designed BCN-RC 1 was carried out on 946 men from two other institutions in the same metropolitan area, using the same criteria of PCa suspicion and diagnostic approach, yielded a csPCa detection rate of 40.8%. The areas under the receiver operating characteristic curves of BCN-RC 1 were 0.823 (95% CI: 0.800–0.846) in the development cohort and 0.837 (95% CI: 0.811–0.863) in the validation cohort (p = 0.447). In both cohorts, BCN-RC 1 exhibited net benefit over performing mpMRI in all men from 8 and 12% risk thresholds, respectively. At 0.95 sensitivity of csPCa, the specificities of BCN-RC 1 were 0.24 (95% CI: 0.22–0.26) in the development cohort and 0.34 (95% CI: 0.31–0.37) in the validation cohort (p < 0.001). The percentages of avoided mpMRI scans were 17.2% in the development cohort and 22.3% in the validation cohort, missing between 1.8% and 2% of csPCa among men at risk of PCa. In summary, BCN-RC 1 can stratify initial PCa suspicion, reducing the demand of mpMRI, with an acceptable loss of csPCa. 000119842 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666 000119842 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000119842 590__ $$a5.2$$b2022 000119842 592__ $$a1.312$$b2022 000119842 591__ $$aONCOLOGY$$b72 / 241 = 0.299$$c2022$$dQ2$$eT1 000119842 593__ $$aOncology$$c2022$$dQ1 000119842 593__ $$aCancer Research$$c2022$$dQ2 000119842 594__ $$a7.4$$b2022 000119842 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000119842 700__ $$0(orcid)0000-0003-0178-4567$$aBorque Fernando, Ángel$$uUniversidad de Zaragoza 000119842 700__ $$aTriquell, Marina 000119842 700__ $$aCampistol, Miriam 000119842 700__ $$aCelma, Anna 000119842 700__ $$aRegis, Lucas 000119842 700__ $$aAbascal, José M. 000119842 700__ $$aServian, Pol 000119842 700__ $$aPlanas, Jacques 000119842 700__ $$aMendez, Olga 000119842 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis M. 000119842 700__ $$aTrilla, Enrique 000119842 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología 000119842 773__ $$g14, 20 (2022), 5100 [14 pp]$$pCancers$$tCancers$$x2072-6694 000119842 8564_ $$s2314902$$uhttps://zaguan.unizar.es/record/119842/files/texto_completo.pdf$$yVersión publicada 000119842 8564_ $$s2893801$$uhttps://zaguan.unizar.es/record/119842/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000119842 909CO $$ooai:zaguan.unizar.es:119842$$particulos$$pdriver 000119842 951__ $$a2024-03-18-15:10:24 000119842 980__ $$aARTICLE